Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
3.450
+0.130 (3.92%)
At close: Oct 8, 2025, 4:00 PM EDT
3.410
-0.040 (-1.16%)
After-hours: Oct 8, 2025, 5:57 PM EDT
Achieve Life Sciences Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Achieve Life Sciences stock has a target of 12, which predicts a 247.83% increase from the current stock price of 3.45.
Price Target: $12 (+247.83%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 21, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Achieve Life Sciences is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +247.83% | Aug 21, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +247.83% | Nov 14, 2024 |
| Raymond James | Raymond James | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +479.71% | Sep 27, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 | Buy | Reiterates | $11 | +218.84% | Aug 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 → $11 | Buy | Maintains | $18 → $11 | +218.84% | May 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
18.72M
EPS This Year
-1.23
from -1.24
EPS Next Year
-1.06
from -1.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 29.8M | |||
| Avg | n/a | 18.7M | |||
| Low | n/a | 8.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.18 | -0.62 | |||
| Avg | -1.23 | -1.06 | |||
| Low | -1.40 | -1.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.